Guardian Pharmacy Services (NYSE:GRDN) Sets New 52-Week High – Time to Buy?

Shares of Guardian Pharmacy Services, Inc. (NYSE:GRDN) reached a new 52-week high during mid-day trading on Tuesday. The stock traded as high as $48.77 and last traded at $48.31, with a volume of 275,237 shares changing hands. The stock had previously closed at $47.02.

Analyst Upgrades and Downgrades

GRDN has been the topic of a number of recent analyst reports. Weiss Ratings raised shares of Guardian Pharmacy Services from a “buy (b-)” rating to a “buy (b)” rating in a research report on Monday. KeyCorp assumed coverage on shares of Guardian Pharmacy Services in a research note on Tuesday, September 22nd. They issued an “overweight” rating and a $52.00 price objective for the company. Wall Street Zen lowered shares of Guardian Pharmacy Services from a “buy” rating to a “hold” rating in a research note on Sunday, October 25th. Truist Financial raised their target price on shares of Guardian Pharmacy Services from $47.00 to $51.00 and gave the company a “buy” rating in a research note on Monday, September 21st. Finally, Oppenheimer lifted their target price on shares of Guardian Pharmacy Services from $43.00 to $49.00 and gave the stock an “outperform” rating in a report on Friday, August 7th. Nine investment analysts have rated the stock with a Buy rating and one has given a Hold rating to the company. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $45.57.

Guardian Pharmacy Services Price Performance

The firm has a market cap of $3.17 billion, a P/E ratio of 42.83, a PEG ratio of 2.60 and a beta of 0.06. The company’s 50 day moving average is $42.09 and its two-hundred day moving average is $38.58.

Guardian Pharmacy Services (NYSE:GRDN) last issued its quarterly earnings results on Thursday, November 5th. The company reported $0.33 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.31 by $0.02. The firm had revenue of $371.07 million for the quarter, compared to analyst estimates of $365.76 million. Guardian Pharmacy Services had a return on equity of 30.29% and a net margin of 5.13%. Research analysts predict that Guardian Pharmacy Services, Inc. will post 1.18 EPS for the current year.

Institutional Trading of Guardian Pharmacy Services

A number of institutional investors and hedge funds have recently modified their holdings of GRDN. First Trust Advisors LP bought a new position in Guardian Pharmacy Services in the first quarter worth $3,528,000. Globeflex Capital L P acquired a new position in shares of Guardian Pharmacy Services in the 2nd quarter valued at $1,857,000. Dimensional Fund Advisors LP raised its stake in shares of Guardian Pharmacy Services by 200.0% in the 1st quarter. Dimensional Fund Advisors LP now owns 208,594 shares of the company’s stock valued at $7,855,000 after buying an additional 139,070 shares in the last quarter. Bank of America Corp DE raised its stake in shares of Guardian Pharmacy Services by 86.1% in the 1st quarter. Bank of America Corp DE now owns 128,048 shares of the company’s stock valued at $4,822,000 after buying an additional 59,245 shares in the last quarter. Finally, Sanctuary Advisors LLC bought a new position in shares of Guardian Pharmacy Services during the 1st quarter worth about $1,352,000.

About Guardian Pharmacy Services

Guardian Pharmacy Services, Inc. provides pharmacy services to people living in long-term care and residential care settings. Its customers include assisted living and skilled nursing communities, behavioral health facilities, and other group-living providers. The company supplies prescription medications and offers medication packaging, delivery, consulting, and clinical support. Its services are designed to help care providers manage residents’ medication needs and support continuity of care. Founded in 2004, Guardian operates a network of pharmacies serving communities across the United States.